Issues discussed at a meeting with the Office of Management & Budget included increasing Medicare reimbursement for physicians, telemedicine permanence, removing G2211 restrictions, adequate reimbursement for therapies and more flexibility for chemotherapy administration codes. The proposed rule is currently under review by the OMB, which is usually the last step prior to releasing publicly for stakeholder review and comment.
My Reflections on Research Cuts
For decades, the U.S. has served as a beacon to the international scientific community. With drastic cuts to scientific investment proposed and implemented, the U.S. stands to lose not only immigrants considering careers in research, but also homegrown scientists. Christina Downey, MD, reflects on the cuts and invites members to be part of the solution.
The ACR Calls on CMS, OMB to Reduce Burdensome Healthcare Regulations
In response to agency requests for feedback on how to streamline regulations and reduce administrative burden on Medicare program stakeholders and small business owners, the ACR called for the removal of certain regulations related to prior authorization, pharmacy benefit managers and Medicare Part B and Part D access.
ACR Responds to Aetna Specialty Pharmacy Requirements
Aetna recently notified practices about the launch of its Combined Benefit Management Drug List, which will result in romosozumab-aqqg (Evenity) and infliximab (Remicade) moving to pharmacy-only coverage on July 1. The ACR is working to oppose this change.
ACR Executive Committee Holds Meetings with Heads of FDA, CMS
As in past administrations, members of the Executive Committee scheduled meetings with leaders of the Food & Drug Administration and Centers for Medicare & Medicaid Services to discuss ACR policy priorities and agency agendas.
ACR, Arthritis Foundation Host Congressional Briefing to Champion Rheumatology Research
The May 6 event brought together patients, physicians and advocates to challenge misconceptions and advocate for sustained investment in rheumatology research.
Underwater Biosimilars Coalition Shares Results of Practice Survey with Congressional Leaders
This week, the Coalition sent Congressional leadership a letter detailing the results of a recent survey about how underwater biosimilars are impacting physicians’ ability to provide high-quality care. Almost all of the nearly 200 practices queried reported being underwater on several biosimilars, with rituximab and infliximab biosimilars being the most common.
ACR Monitoring HHS Workforce Reductions, Function Consolidations
Changes announced April 1 will cut 10,000 positions at the U.S. Department of Health & Human Services and consolidate many department functions. The ACR is monitoring how these changes may impact regulatory issues of concern to ACR members.
State Legislative Update, Spring 2025
With the state legislative session in full swing, the ACR is currently tracking 114 pieces of state legislation across many issue areas, including utilization management, prescription drug review boards and vaccines.
CMS Nominee Mehmet Oz’s Stated Policy Priorities & Rheumatology
With Mehmet Oz, MD, expected to be confirmed as administrator of the Centers for Medicare & Medicaid Services, the ACR considers how his stated priorities may affect rheumatology.
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 11
- Next Page »